FSD Pharma Inc. HUGE
Day range unavailable
52-week range unavailable
- Market cap
- 66.67K
- Shares out
- 708.61K
- Forward P/E
- -0.75
- Analysts
- Buy
- Price target
- 2.60 (+2792.1%)
- Earnings date
- Aug 14, 2024
YTD -54.68 (-93.47%)
Key statistics
- Enterprise value
- 287.16K
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.01
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -10.05M
- Total cash
- 3.33M
- Total debt
- 625.20K
- Return on equity
- -63.89%
- Short % of float
- 0.44%
- 50-day average
- 8.13
- 200-day average
- 36.69
Analyst view
Consensus: buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.06.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 14, 2024 | Jun 1, 2024 | -0.06 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.05 | — | — | — |
| Mar 28, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Jul 20, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 12, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
About FSD Pharma Inc.
FSD Pharma Inc., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. FSD Pharma Inc. is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- Canada
- Website
- fsdpharma.com
News
Court Sides with Quantum BioPharma in Dispute with Dr. Bokhari, Legal Battle Continues Over $2.8M Award 
Quantum BioPharma Invites Shareholders To The $700M+ Court Case The Company Has Filed Against CIBC, RBC, And Others For Alleged Spoofing/Stock Price Manipulation - 'Majority Of Voters Support Marijuana Business Banking Access, Saying It Will Improve Public Safety And Equity, New Poll Finds' - Marijuanamoment
'North Dakota Voters Will Decide On Marijuana Legalization At The Ballot This November, State Certifies' -Marijuana Moment Report 
'Booker Says There's Republican Support For 'SAFE Banking Plus' Marijuana Compromise' -Marijuana Moment Report 
Politico Reporter Tweets: Congress appears ready to send the first-ever cannabis bill to POTUS' desk - 'D.C. Mayor Signs Bill Providing Workplace Protections For Marijuana Consumers' -Marijuana Moment Report
Stocks That Hit 52-Week Lows On Friday - Stocks That Hit 52-Week Lows On Wednesday
- AP Reported Earlier Germany Moves Ahead with Plan to Legalize Cannabis Sales
Your note
Sign in to keep a note on HUGE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Bokhari (Raza) | 10% Security Holder of Issuer | Redemption, retraction, cancelation, repurchase | Mar 28, 2022 | 5,527 |
| Carroll (Donal) | Director of Issuer | Acquisition or disposition in the public market | Sep 26, 2022 | 263,444 |
| Coyle (Nathan Patrick) | Senior Officer of Issuer | Acquisition or disposition in the public market | Jun 9, 2022 | 2,500 |
| Durkacz (Anthony John) | 10% Security Holder of Issuer | Acquisition or disposition in the public market | Apr 24, 2022 | 273,597 |
| FSD Pharma, Inc. | Issuer | Redemption, retraction, cancelation, repurchase | Sep 25, 2022 | 219,400 |
| Kotra (Lakshmi) | Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) | Acquisition or disposition in the public market | Dec 6, 2021 | 298,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Investments, LLC | 0.63% | 249,305 | 286.70K | Jun 29, 2023 |
| Renaissance Technologies, LLC | 0.26% | 102,600 | 117.99K | Jun 29, 2023 |
| Susquehanna International Group, LLP | 0.15% | 57,465 | 66.08K | Jun 29, 2023 |
| Janney Montgomery Scott LLC | 0.04% | 15,000 | 17.25K | Jun 29, 2023 |
| Two Sigma Securities, LLC | 0.03% | 10,165 | 11.69K | Jun 29, 2023 |
| Royal Bank of Canada | 0.01% | 2,176 | 2.50K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 0.60% | 235,637 | 285.26K | Sep 29, 2023 |